Inflammation and cancer
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 8 of the 94 sources its claims cite were checked for support.
Abstract
Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
Overview
CoChat Summary
TL;DR
This review argues that inflammation is a critical component of tumour progression, with inflammatory cells and their mediators fostering proliferation, survival, angiogenesis, invasion and metastasis. It synthesizes evidence linking chronic infection/inflammation to cancer and discusses anti-inflammatory therapeutic opportunities.
Key findings
- Many cancers arise from sites of infection, chronic irritation and inflammation; the tumour microenvironment, largely orchestrated by inflammatory cells, is an indispensable participant in neoplasia, fostering proliferation, survival and migration.
- Upwards of 15% of malignancies worldwide are attributable to infections, a global total of 1.2 million cases per year; chronic inflammatory conditions are associated with neoplasms including colorectal carcinoma in inflammatory bowel disease and gastric cancer with chronic *Helicobacter pylori* infection, the second most common cancer globally.
- In MMTV-PyMT mammary cancer mice crossed with CSF-1-null (*Csf1op*) mice, absence of CSF-1 had no apparent early consequence, but late-stage invasive carcinoma and pulmonary metastases were significantly attenuated; targeting CSF-1 to mammary epithelium restored macrophage recruitment, primary tumour development and metastatic potential.
- Long-term aspirin/NSAID use reduces colon cancer risk by 40–50% and may be preventative for lung, oesophagus and stomach cancer; tumour cells also co-opt innate immune signalling molecules such as selectins, chemokines and their receptors for invasion, migration and metastasis.
Methods
- Narrative review; no primary experiments or new patient/animal data are reported.
- Synthesizes published literature on inflammation, innate immunity, wound healing, inflammatory cell types, chemokines, chronic inflammation-associated cancers, selectin/MMP biology and anti-inflammatory therapy.
- Main analysis is conceptual synthesis and interpretation of cited studies; no systematic search strategy, inclusion criteria or quantitative meta-analysis is described.
Limitations
- The paper states that the acquired immune response to cancer is intimately related to the inflammatory response but is beyond the scope of the article.
- Evident from the text: as a narrative review, it lacks a systematic search or formal evidence appraisal, and conclusions depend on the cited studies.
- Evident from the text: many molecular and cellular mechanisms mediating the inflammation–cancer relationship remain unresolved, and therapeutic implications are largely based on observational, animal or preclinical evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 1 Not valid · 66 Not checked · 35 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to altering the local balance of pro-angiogenic factors during melanoma development, during human cervical carcinogenesis, TAMs express VEGF-C and VEGF-D as well as the VEGF receptor-3 (VEGFR-3), all of which are implicated in formation of lymphatic vessels and lymphatic metastases17.”
What the sources say
- Supportedcites [17] Schoppmann S, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947–956. doi: 10.1016/S0002-9440(10)64255-1. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Abstract (p.1) states that in human cervical cancers the VEGF-C- and VEGF-D-producing stromal cells were identified in situ as a subset of activated TAMs (CD68, CD23, CD14) that 'also expressed the VEGF-C-and VEGF-D-specific tyrosine kinase receptor VEGFR-3'. The Discussion reinforces this: 'All VEGF-C-and VEGF-D-producing TAMs co-expressed also the corresponding tyrosine kinase receptor VEGFR-3', and links their density to peritumoral lymphatic microvessel density, lymphangiosis carcinomatosa and lymph-node metastasis, i.e. lymphatic vessel formation and lymphatic spread. The melanoma clause of the citing sentence belongs to a different citation and was not judged here. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tumour cells produce various cytokines and chemokines that attract leukocytes.”
What the sources say
- Could not verifycites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Helicobacter pylori section (p. 9) describes white blood cells being attracted during inflammation, followed by increased cytokine production. The Mechanisms section (p. 2) discusses inflammation caused by infection. Neither passage says that tumour cells produce cytokines or chemokines to attract leukocytes; searches for those terms found no supporting passage. (LLM, conf=0.76)
- Partly supportedcites [12] Wahl LM, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst. 1998;90:1583–1584. doi: 10.1093/jnci/90.21.1583. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
On p. 1, the paper says tumor-derived attractants, including monocyte chemotactic protein-1, recruit tumor-associated macrophages to tumors. It also lists several tumor-derived cytokines, but describes them as reducing macrophage cytotoxicity, not attracting leukocytes. The claim extends the recruitment point beyond the macrophages and attractant discussed in the paper. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The key difference between PyMT mice and PyMT/Csf1op/Csf1op mice is not in the apparent proliferative capacity of neoplastic epithelial cells, but in the failure to recruit mature macrophages into neoplastic tissue in the absence of CSF-1.”
What the sources say
- Supportedcites [21] Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727–740. doi: 10.1084/jem.193.6.727. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Introduction reports that CSF-1 deficiency did not affect primary mammary tumor growth but delayed macrophage recruitment. The Results section (“Absence of CSF-1 Does Not Effect Growth of the Primary Mammary Tumor”) found no significant difference in tumor-cell proliferation, and the Discussion reports no macrophage infiltration at the tumor site in CSF-1-null PyMT mice. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
What the sources say
- Partly supportedcites [11] Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183. doi: 10.1046/j.1365-2796.2000.00742.x. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Mechanisms section (p. 2) says inflammatory phagocytes produce reactive oxygen and nitrogen species that can favor carcinogenesis. The H. pylori section (p. 9) links recruited white blood cells and cytokines to oxidative DNA damage. Neither passage establishes the claimed contribution of all four named cell types through extracellular proteases, pro-angiogenic factors, and chemokines, or cites genetic and functional experiments for it. (LLM, conf=0.78)
- Not checked yetcites [23] DiCarlo E, et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood. 2001;97:339–345. doi: 10.1182/blood.v97.2.339. [DOI] [PubMed] [Google Scholar] source
- Partly supportedcites [24] Coussens LM, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13:1382–1397. doi: 10.1101/gad.13.11.1382. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) links mast cells to angiogenesis during premalignant squamous carcinogenesis through the release of pro-angiogenic proteases. The paper does not establish the claimed roles of neutrophils, eosinophils or activated T lymphocytes, or their release of chemokines. (LLM, conf=0.86)
- Not checked yetcites [25] Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–490. doi: 10.1016/s0092-8674(00)00139-2. [DOI] [PMC free article] [PubMed] [Google Scholar] source
- Partly supportedcites [26] Bergers G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2000;2:737–744. doi: 10.1038/35036374. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies mast cells and neutrophils as suppliers of MMP-9 in a model of squamous carcinogenesis, and reports that MMP-9 can mobilize VEGF during angiogenesis. Our copy does not establish the claimed roles for eosinophils or activated T lymphocytes, or say that these cells contribute by releasing chemokines. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“Indeed, macrophage infiltration is closely associated with the depth of invasion of primary melanoma due, in part, to macrophage-regulated tumour-associated angiogenesis19.”
What the sources say
- Not checked yetcites [19] Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother Pharmacol. 1999;43:S69–S71. doi: 10.1007/s002800051101. [DOI] [PubMed] [Google Scholar] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
76 more claims
Create a free account to see all 107 claims and to verify the 86 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic inflammation is also important for carcinogenesis, as pro-inflammatory cytokines, including IL-1β, can be tumour promoting6,111.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammatory cells such as macrophages and neutrophils can cause immunosuppression in the TME.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Self-citationMatrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Self-citationThe Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410 · cited 1×
“A family of chemotactic cytokines, named chemokines, which possess a relatively high degree of specificity for chemoattraction of specific leukocyte population”
Cited by
Items 801–900 of 1,179
A chemokine receptor antagonist inhibits experimental breast tumor growth.
Robinson, S. C., Scott, K. A., Wilson, J. L., Thompson, R. G., Proudfoot, A. E. I., & Balkwill, F. R. (2003) · PubMed · Cited by 287
Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and Cancer
Talero, E., García-Mauriño, S., Ávila-Román, J., Rodríguez-Luna, A., Alcaide, A., & Motilva, V. (2015) · Marine Drugs · doi:10.3390/md13106152 · Cited by 255
Gal-Ben-Ari, S., Barrera, I., Ehrlich, M., & Rosenblum, K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00480 · Cited by 254
Gut microbiota, inflammation and colorectal cancer
Sun, J., & Kato, I. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.03.004 · Cited by 257
Telomerase: central regulator of all of the hallmarks of cancer
Low, K. C., & Tergaonkar, V. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.07.001 · Cited by 257
Schmall, A., Al-tamari, H. M., Herold, S., Kampschulte, M., Weigert, A., Wietelmann, A., Vipotnik, N., Grimminger, F., Seeger, W., Pullamsetti, S. S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1137oc · Cited by 259
The role of pattern recognition receptors in intestinal inflammation
Fukata, M., & Arditi, M. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.13 · Cited by 253
Xu, P., & Derynck, R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.034 · Cited by 257
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256
Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts
Laberge, R.-M., Awad, P., Campisi, J., & Desprez, P.-Y. (2012) · Cancer Microenvironment · doi:10.1007/s12307-011-0069-4 · Cited by 255
Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control
Fridman, W. H., Galon, J., Dieu-Nosjean, M.-C., Cremer, I., Fisson, S., Damotte, D., Pagès, F., Tartour, E., & Sautès-Fridman, C. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_46 · Cited by 258
The Inflammation and Liver Cancer
Bishayee, A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_16 · Cited by 255
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients
Glynn, S. A., Boersma, B. J., Dorsey, T. H., Yi, M., Yfantis, H. G., Ridnour, L. A., Martin, D. N., Switzer, C. H., Hudson, R. S., Wink, D. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42059 · Cited by 254
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions
Noonan, D. M., De Lerma Barbaro, A., Vannini, N., Mortara, L., & Albini, A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9108-5 · Cited by 253
Hasselbalch, H. C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2012.10.020 · Cited by 254
The multifaceted roles of chemokines in malignancy
Ben-Baruch, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9003-5 · Cited by 259
Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., & Hanahan, D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00271-x · Cited by 211
Circulating Epithelial Cells in Patients with Benign Colon Diseases
Pantel, K., Denève, E., Nocca, D., Coffy, A., Vendrell, J.-P., Maudelonde, T., Riethdorf, S., & Alix-Panabières, C. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.175570 · Cited by 255
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
Broekman, F. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i2.80 · Cited by 247
Oxidatively induced DNA damage and its repair in cancer
Dizdaroglu, M. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.002 · Cited by 254
Urinary biomarkers of oxidative status
Il'yasova, D., Scarbrough, P., & Spasojevic, I. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.06.012 · Cited by 235
Lymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
Self-citationThe role of the myofibroblast in tumor stroma remodeling
Otranto, M., Sarrazy, V., Bonté, F., Hinz, B., Gabbiani, G., & Desmouliere, A. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20377 · Cited by 250
Mouse regulatory DNA landscapes reveal global principles of cis-regulatory evolution
Vierstra, J., Rynes, E., Sandstrom, R., Zhang, M., Canfield, T., Hansen, R. S., Stehling-Sun, S., Sabo, P. J., Byron, R., Humbert, R., et al. (2014) · Science · doi:10.1126/science.1246426 · Cited by 257
TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives
Tammaro, A., Derive, M., Gibot, S., Leemans, J. C., Florquin, S., & Dessing, M. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.043 · Cited by 253
Cancer evolution: Darwin and beyond
Vendramin, R., Litchfield, K., & Swanton, C. (2021) · The EMBO Journal · doi:10.15252/embj.2021108389 · Cited by 252
Platelets: a critical link between inflammation and microvascular dysfunction
Stokes, K. Y., & Granger, D. N. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.225417 · Cited by 256
The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression
Wang, H., Yung, M. M. H., Ngan, H. Y. S., Chan, K. K. L., & Chan, D. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126560 · Cited by 254
The circadian clock in cancer development and therapy
Fu, L., & Kettner, N. M. (2013) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-396971-2.00009-9 · Cited by 251
Jung, M. R., Park, Y. K., Jeong, O., Seon, J. W., Ryu, S. Y., Kim, D. Y., & Kim, Y. J. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21986 · Cited by 251
Cellular and molecular aspects of gastric cancer
Smith, M. G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i19.2979 · Cited by 252
Energy Balance, Host-Related Factors, and Cancer Progression
Hursting, S. D., & Berger, N. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.27.9935 · Cited by 252
Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer
Shabani, F., Farasat, A., Mahdavi, M., & Gheibi, N. (2018) · Inflammation Research · doi:10.1007/s00011-018-1173-4 · Cited by 246
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A. M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111497 · Cited by 250
Inflammation and Endometrial Cancer: A Hypothesis
Modugno, F., Ness, R. B., Chen, C., & Weiss, N. S. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0493 · Cited by 254
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors
Thompson, E. D., Enriquez, H. L., Fu, Y.-X., & Engelhard, V. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092454 · Cited by 249
Ferrara, N. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-07-0590 · Cited by 251
Cellular and molecular pathways linking inflammation and cancer
Porta, C., Larghi, P., Rimoldi, M., Grazia Totaro, M., Allavena, P., Mantovani, A., & Sica, A. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.06.014 · Cited by 250
The Role of Inflammation in Lung Cancer
Gomes, M., Teixeira, A. L., Coelho, A., Araújo, A., & Medeiros, R. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-0348-0837-8_1 · Cited by 205
SPARC and tumor growth: Where the seed meets the soil?
Framson, P. E., & Sage, E. H. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20091 · Cited by 249
RETRACTED: Chronic Inflammation: Accelerator of Biological Aging
Fougère, B., Boulanger, E., Nourhashémi, F., Guyonnet, S., & Cesari, M. (2017) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glw240 · Cited by 247
RetractedChang, M., Hou, Z., Jin, D., Zhou, J., Wang, M., Wang, M., Shu, M., Ding, B., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004647 · Cited by 249
Azab, B., Shah, N., Radbel, J., Tan, P., Bhatt, V., Vonfrolio, S., Habeshy, A., Picon, A., & Bloom, S. (2013) · Medical Oncology · doi:10.1007/s12032-012-0432-4 · Cited by 249
Lee, J. H., Khor, T. O., Shu, L., Su, Z.-Y., Fuentes, F., & Kong, A.-N. T. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.008 · Cited by 247
The role of Toll-like receptors in chronic inflammation
Drexler, S. K., & Foxwell, B. M. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.10.009 · Cited by 248
Imayama, I., Ulrich, C. M., Alfano, C. M., Wang, C., Xiao, L., Wener, M. H., Campbell, K. L., Duggan, C., Foster-Schubert, K. E., Kong, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3092 · Cited by 249
Cancer and the Complement Cascade
Rutkowski, M. J., Sughrue, M. E., Kane, A. J., Mills, S. A., & Parsa, A. T. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0225 · Cited by 250
Genistein: Its role in metabolic diseases and cancer
Mukund, V., Mukund, D., Sharma, V., Mannarapu, M., & Alam, A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.004 · Cited by 249
Visceral adiposity, insulin resistance and cancer risk
Donohoe, C. L., Doyle, S. L., & Reynolds, J. V. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-12 · Cited by 247
Liu, J., Zhang, N., Li, Q., Zhang, W., Ke, F., Leng, Q., Wang, H., Chen, J., & Wang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019495 · Cited by 245
A20: from ubiquitin editing to tumour suppression
Hymowitz, S. G., & Wertz, I. E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2775 · Cited by 247
“For example, patients with chronic ulcerative colitis have an increased incidence of colonic adenocarcinoma, patients harbouring Helicobacter pylori infections more commonly develop mucosa-associated lymphomas and hepatocellular carcinoma is more frequent in patients infected with hepatitis C viru”
BackgroundAlfarouk, K. O., Verduzco, D., Rauch, C., Muddathir, A. K., Bashir, A. H. H., Elhassan, G. O., Ibrahim, M. E., Orozco, J. D. P., Cardone, R. A., Reshkin, S. J., et al. (2014) · Oncoscience · doi:10.18632/oncoscience.109 · Cited by 245
Zhu, X., Mulcahy, L. A., Mohammed, R. A., Lee, A. H., Franks, H. A., Kilpatrick, L., Yilmazer, A., Paish, E. C., Ellis, I. O., Patel, P. M., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2195 · Cited by 250
Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases
Gupta, S. C., Kunnumakkara, A. B., Aggarwal, S., & Aggarwal, B. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02160 · Cited by 243
Fen1 mutations result in autoimmunity, chronic inflammation and cancers
Zheng, L., Dai, H., Zhou, M., Li, M., Singh, P., Qiu, J., Tsark, W., Huang, Q., Kernstine, K., Zhang, X., et al. (2007) · Nature Medicine · doi:10.1038/nm1599 · Cited by 247
Epidemiology of Inflammation and Prostate Cancer
PLATZ, E. A., & De MARZO, A. M. (2004) · Journal of Urology · doi:10.1097/01.ju.0000108131.43160.77 · Cited by 243
Mirabello, L., Huang, W., Wong, J. Y. Y., Chatterjee, N., Reding, D., David Crawford, E., De Vivo, I., Hayes, R. B., & Savage, S. A. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00485.x · Cited by 248
Hyperplastic gastric tumors induced by activated macrophages in COX‐2/mPGES‐1 transgenic mice
Oshima, H., Oshima, M., Inaba, K., & Taketo, M. M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600170 · Cited by 251
Protease-Activated Drug Development
Choi, K. Y., Swierczewska, M., Lee, S., & Chen, X. (2012) · Theranostics · doi:10.7150/thno.4068 · Cited by 245
Periodontal disease and cancer: Epidemiologic studies and possible mechanisms
Nwizu, N., Wactawski‐Wende, J., & Genco, R. J. (2020) · Periodontology 2000 · doi:10.1111/prd.12329 · Cited by 239
List, K., Szabo, R., Molinolo, A., Sriuranpong, V., Redeye, V., Murdock, T., Burke, B., Nielsen, B. S., Gutkind, J. S., & Bugge, T. H. (2005) · Genes & Development · doi:10.1101/gad.1300705 · Cited by 247
The Inflammatory Tumor Microenvironment and Its Impact on Cancer Development
de Visser, K. E., & Coussens, L. M. (2006) · Contributions to Microbiology · doi:10.1159/000092969 · Cited by 247
Self-citationPregnancy and Breast Cancer: when They Collide
Lyons, T. R., Schedin, P. J., & Borges, V. F. (2009) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-009-9119-7 · Cited by 239
Matrix metalloproteinases involvement in pathologic conditions.
Amălinei, C., Căruntu, I.-D., Giuşcă, S. E., & Balan, R. A. (2010) · PubMed · Cited by 246
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Bayliss, T. J., Smith, J. T., Schuster, M., Dragnev, K. H., & Rigas, J. R. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.627850 · Cited by 243
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation
Lanaya, H., Natarajan, A., Komposch, K., Li, L., Amberg, N., Chen, L., Wculek, S. K., Hammer, M., Zenz, R., Peck-Radosavljevic, M., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3031 · Cited by 242
Effect of Ginger on Inflammatory Diseases
Ballester, P., Cerdá, B., Arcusa, R., Marhuenda, J., Yamedjeu, K., & Zafrilla, P. (2022) · Molecules · doi:10.3390/molecules27217223 · Cited by 214
The Ribosome Biogenesis—Cancer Connection
Penzo, M., Montanaro, L., Treré, D., & Derenzini, M. (2019) · Cells · doi:10.3390/cells8010055 · Cited by 242
Elastin‐Elastases and Inflamm‐Aging
Antonicelli, F., Bellon, G., Debelle, L., & Hornebeck, W. (2007) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)79005-6 · Cited by 240
Muller, A. J., Sharma, M. D., Chandler, P. R., DuHadaway, J. B., Everhart, M. E., Johnson, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806173105 · Cited by 240
Oral microbiome and oral and gastrointestinal cancer risk
Ahn, J., Chen, C. Y., & Hayes, R. B. (2012) · Cancer Causes & Control · doi:10.1007/s10552-011-9892-7 · Cited by 238
Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy
Mishra, P., Banerjee, D., & Ben-Baruch, A. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310182 · Cited by 239
Epigallocatechin 3-gallate: From green tea to cancer therapeutics
Alam, M., Ali, S., Ashraf, G. M., Bilgrami, A. L., Yadav, D. K., & Hassan, M. I. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2022.132135 · Cited by 236
Ageing: from inflammation to cancer
Leonardi, G. C., Accardi, G., Monastero, R., Nicoletti, F., & Libra, M. (2018) · Immunity & Ageing · doi:10.1186/s12979-017-0112-5 · Cited by 241
Loberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J. (2007) · Neoplasia · doi:10.1593/neo.07307 · Cited by 242
Lu, Y., Cai, Z., Galson, D. L., Xiao, G., Liu, Y., George, D. E., Melhem, M. F., Yao, Z., & Zhang, J. (2006) · The Prostate · doi:10.1002/pros.20464 · Cited by 242
The association between periodontal disease and cancer: A review of the literature
Fitzpatrick, S. G., & Katz, J. (2010) · Journal of Dentistry · doi:10.1016/j.jdent.2009.10.007 · Cited by 244
HPV-DNA Integration and Carcinogenesis: Putative Roles For Inflammation And Oxidative Stress
Williams, V. M., Filippova, M., Soto, U., & Duerksen-Hughes, P. J. (2011) · Future Virology · doi:10.2217/fvl.10.73 · Cited by 236
Dual Roles for Immunity in Gastrointestinal Cancers
Ferrone, C., & Dranoff, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.27.9992 · Cited by 241
The Tumor Microenvironment in Colorectal Carcinogenesis
Peddareddigari, V. G., Wang, D., & DuBois, R. N. (2010) · Cancer Microenvironment · doi:10.1007/s12307-010-0038-3 · Cited by 237
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?
Jarnicki, A., Putoczki, T., & Ernst, M. (2010) · Cell Division · doi:10.1186/1747-1028-5-14 · Cited by 240
Oxidative stress, eryptosis and anemia: a pivotal mechanistic nexus in systemic diseases
Bissinger, R., Bhuyan, A. A. M., Qadri, S. M., & Lang, F. (2019) · The FEBS Journal · doi:10.1111/febs.14606 · Cited by 239
A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism
Pribluda, A., Elyada, E., Wiener, Z., Hamza, H., Goldstein, R. E., Biton, M., Burstain, I., Morgenstern, Y., Brachya, G., Billauer, H., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.005 · Cited by 239
Echizen, K., Hirose, O., Maeda, Y., & Oshima, M. (2016) · Cancer Science · doi:10.1111/cas.12901 · Cited by 238
Biological actions and molecular effects of resveratrol, pterostilbene, and 3′-hydroxypterostilbene
Tsai, H.-Y., Ho, C.-T., & Chen, Y.-K. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2016.07.004 · Cited by 234
Oshima, H., Matsunaga, A., Fujimura, T., Tsukamoto, T., Taketo, M. M., & Oshima, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.014 · Cited by 240
Wu, J., Li, J., Salcedo, R., Mivechi, N. F., Trinchieri, G., & Horuzsko, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0938 · Cited by 238
Host Factors and Cancer Progression: Biobehavioral Signaling Pathways and Interventions
Lutgendorf, S. K., Sood, A. K., & Antoni, M. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9357 · Cited by 237
TGR5, Not Only a Metabolic Regulator
Guo, C., Chen, W.-D., & Wang, Y.-D. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00646 · Cited by 236
Malnutrition in cancer patients: Causes, consequences and treatment options
Arends, J. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.107074 · Cited by 215
Tian, R., Hou, G., Li, D., & Yuan, T.-F. (2014) · The Scientific World Journal · doi:10.1155/2014/780616 · Cited by 237
Serum Biomarker Panels for the Detection of Pancreatic Cancer
Brand, R. E., Nolen, B. M., Zeh, H. J., Allen, P. J., Eloubeidi, M. A., Goldberg, M., Elton, E., Arnoletti, J. P., Christein, J. D., Vickers, S. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0248 · Cited by 239
Dietary Inflammatory Index and Colorectal Cancer Risk—A Meta-Analysis
Shivappa, N., Godos, J., Hébert, J., Wirth, M., Piuri, G., Speciani, A., & Grosso, G. (2017) · Nutrients · doi:10.3390/nu9091043 · Cited by 232
He, W., Kapate, N., Shields, C. W., & Mitragotri, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.12.001 · Cited by 236
Exploring the multifocal role of phytochemicals as immunomodulators
Behl, T., Kumar, K., Brisc, C., Rus, M., Nistor-Cseppento, D. C., Bustea, C., Aron, R. A. C., Pantis, C., Zengin, G., Sehgal, A., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110959 · Cited by 219
Mushrooms: A Potential Natural Source of Anti-Inflammatory Compounds for Medical Applications
Elsayed, E. A., El Enshasy, H., Wadaan, M. A. M., & Aziz, R. (2014) · Mediators of Inflammation · doi:10.1155/2014/805841 · Cited by 236
The receptor RAGE: Bridging inflammation and cancer
Riehl, A., Németh, J., Angel, P., & Hess, J. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-12 · Cited by 231
Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer
Amin, M. N., Siddiqui, S. A., Ibrahim, M., Hakim, M. L., Ahammed, M. S., Kabir, A., & Sultana, F. (2020) · SAGE Open Medicine · doi:10.1177/2050312120965752 · Cited by 227
Regulation of IL-6 in Immunity and Diseases
Tanaka, T., Narazaki, M., Masuda, K., & Kishimoto, T. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-024-0921-5_4 · Cited by 235
Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., Magdeleinat, P., Mami-Chouaib, F., Dieu-Nosjean, M.-C., Fridman, W.-H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36551 · Cited by 237
Metadata
- Authors
- Coussens, L. M., & Werb, Z.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Nature
- Published
- 2002-12
- Volume
- 420
- Issue
- 6917
- Pages
- 860-867
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2803035
- OpenAlex
- W1965037168
- Cited by
- 15,111
- References
- 88
- Citations by year
- 2026: 328 · 2025: 590 · 2024: 701 · 2023: 849 · 2022: 873 · 2021: 934 · 2020: 858 · 2019: 827 · 2018: 742 · 2017: 775 · 2016: 756 · 2015: 773 · 2014: 776 · 2013: 749 · 2012: 689
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- V Foundation for Cancer Research
- Edward Mallinckrodt, Jr. Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- inflammation, cancer, tumor microenvironment, tumor progression, chronic inflammation, infection-associated cancer, inflammatory cells, tumor cell proliferation, cell migration, metastasis, innate immune signaling, selectins, chemokines, chemokine receptors
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Leukocytes, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Disease Progression, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.